RecruitingPhase IIEN originalLeukemia

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Diagnoza ostrej białaczki limfoblastycznej B (ALL B) z obecnością markera CD19.
  • Pacjenci w wieku 40 lat lub starsi.
  • Pacjenci w wieku 30-39 lat, jeśli mają poważne problemy zdrowotne utrudniające standardowe leczenie lub źle tolerują chemioterapię.
  • Choroba jest w remisji bez wykrywalnych pozostałości nowotworu (MRD-ujemna) lub w remisji z niepełnym powrotem prawidłowej liczby krwinek (CRi).
  • Remisja musi być osiągnięta w ciągu 4 miesięcy od rozpoczęcia leczenia.
  • Pacjenci muszą mieć prawidłowe wyniki badań narządów (wątroby, nerek) i tlenoterapii.

✗ Disqualifies

  • W poprzednim badaniu skupiono się na osobach z pierwszą remisją MRD-ujemną lub CRi, ale nie ma jawnych kryteriów wykluczenia w podanym tekście, poza tymi spełniającymi kryteria włączenia.

Simplified criteria — AI translation

Trial details

Minimum age
40 Years
Last updated (source)
June 29, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (8)

Stanford University (Data Collection AND Specimen Analysis)

Stanford, United States

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, United States

Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities)

Commack, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, United States

Trial contact

Ioannis Kalogirou Valtis, MD

Mark Geyer, MD

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.